Ellsworth Advisors LLC Buys Shares of 48,872 Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Ellsworth Advisors LLC recently acquired a new stake in Centessa Pharmaceuticals PLC, purchasing 48,872 shares worth approximately $703,000 during the first quarter.
• Centessa Pharmaceuticals has received favorable ratings from multiple brokerages, with a consensus rating of "Buy" and a target price averaging $32.70.
• Insider trading activity included significant sales by executives, indicating potential shifts in ownership as insiders sold over 248,000 shares worth around $4 million in recent months.

Ellsworth Advisors LLC bought a new stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 48,872 shares of the company's stock, valued at approximately $703,000.

A number of other large investors also recently modified their holdings of the company. GAMMA Investing LLC increased its holdings in Centessa Pharmaceuticals by 1,509.6% in the first quarter. GAMMA Investing LLC now owns 61,762 shares of the company's stock valued at $888,000 after purchasing an additional 57,925 shares during the period. BNP Paribas Financial Markets acquired a new stake in Centessa Pharmaceuticals in the 4th quarter valued at $162,000. OMERS ADMINISTRATION Corp acquired a new stake in Centessa Pharmaceuticals in the 4th quarter valued at $171,000. Cutter Capital Management LP grew its position in Centessa Pharmaceuticals by 184.3% in the 1st quarter. Cutter Capital Management LP now owns 418,127 shares of the company's stock valued at $6,013,000 after purchasing an additional 271,051 shares during the period. Finally, Cerity Partners LLC purchased a new stake in Centessa Pharmaceuticals in the 1st quarter valued at $471,000. 82.01% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Mario Alberto Accardi sold 15,000 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $14.00, for a total transaction of $210,000.00. Following the completion of the transaction, the insider owned 216,485 shares in the company, valued at approximately $3,030,790. The trade was a 6.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction on Wednesday, June 25th. The stock was sold at an average price of $13.86, for a total transaction of $138,600.00. Following the sale, the insider owned 122,279 shares of the company's stock, valued at approximately $1,694,786.94. This represents a 7.56% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 262,286 shares of company stock worth $4,364,835 in the last ninety days. Company insiders own 7.09% of the company's stock.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ CNTA traded up $0.71 during mid-day trading on Wednesday, hitting $22.04. The stock had a trading volume of 638,651 shares, compared to its average volume of 1,019,432. The company has a debt-to-equity ratio of 0.32, a quick ratio of 10.12 and a current ratio of 10.11. The company has a 50 day moving average of $17.06 and a two-hundred day moving average of $14.71. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $9.60 and a twelve month high of $23.24. The firm has a market cap of $2.95 billion, a PE ratio of -12.30 and a beta of 1.47.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). Research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Truist Financial began coverage on Centessa Pharmaceuticals in a research report on Monday, July 21st. They issued a "buy" rating and a $30.00 target price for the company. Wall Street Zen lowered Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Oppenheimer assumed coverage on Centessa Pharmaceuticals in a research note on Friday, August 29th. They issued an "outperform" rating and a $40.00 target price on the stock. Lifesci Capital upgraded shares of Centessa Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, September 3rd. Finally, Needham & Company LLC started coverage on Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company. Based on data from MarketBeat, Centessa Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $32.44.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.